Show simple item record

dc.date.accessioned2018-06-26T09:29:11Z
dc.date.issued2001en_US
dc.identifierhttp://publications.icr.ac.uk/543/en_US
dc.identifier.citationCURRENT OPINION IN MOLECULAR THERAPEUTICS, 2001, 3 (3), pp. 288 - 294en_US
dc.identifier.issn1464-8431en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1929
dc.format.extent288 - 294en_US
dc.subjectPHOSPHOROTHIOATE OLIGONUCLEOTIDE COMPLEMENTARY HUMAN CYTOMEGALOVIRUS ANTISENSE OLIGONUCLEOTIDE GENE-EXPRESSION INTRAVITREAL INJECTION ANTIVIRAL ACTIVITY RNA PHARMACOKINETICS DISPOSITION INHIBITIONen_US
dc.titleTechnology evaluation: Fomivirsen, Isis pharmaceuticals Inc/CIBA visionen_US
dc.typeJournal Article
rioxxterms.licenseref.startdate2001en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfCURRENT OPINION IN MOLECULAR THERAPEUTICSen_US
pubs.issue3en_US
pubs.notesnoneen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.volume3en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorOrr, Rosanneen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record